Amended Current Report Filing (8-k/a)

Date : 05/09/2019 @ 11:14AM
Source : Edgar (US Regulatory)
Stock : Moderna (MM) (MRNA)
Quote : 13.685  -0.365 (-2.60%) @ 3:13PM

Amended Current Report Filing (8-k/a)

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
  
FORM 8-K/A

(Amendment No. 1)
   CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 8, 2019
 
 
MODERNA, INC.
(Exact name of registrant as specified in its charter)
  
 
 
 
 
 
Delaware
 
001-38753
 
81-3467528
 (State or other jurisdiction of incorporation)
 
 (Commission File Number)
 
 (IRS Employer Identification No.)
 
200 Technology Square
 
 
Cambridge, MA
 
02139
(Address of principal executive offices)
 
(Zip code)


Registrant’s telephone number, including area code: (617) 714-6500

N/A
(Former name or former address, if changed since last report.)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company       x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.        o

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading symbol(s)
Name of each exchange on which registered
Common stock, par value $0.0001 per share
MRNA
The NASDAQ Stock Market LLC







EXPLANATORY NOTE
This Amendment No. 1 on Form 8-K/A (the “Amendment”) amends the Current Report on Form 8-K filed by Moderna, Inc. (the “Company”) on May 8, 2019 (the “Original Form 8-K”). Except as provided below, the Original Form 8-K is otherwise unaltered by this Amendment.

Item 2.02 Results of Operations and Financial Condition.

On May 8, 2019, the Company filed the Original Form 8-K with an accompanying press release announcing its results of operations and financial condition for the first quarter ended March 31, 2019. By this Amendment, the Company is amending and restating Exhibit 99.1 thereof to correct certain typographical errors.

Net Loss was accurately reported under the heading “First Quarter 2019 Financial Results” in the press release accompanying the Original Form 8-K. However, there were typographical errors in the “Other expense, net” line item of the Condensed Consolidated Statements of Operations for the three months ended March 31, 2019 and 2018, which resulted in errors in the “Net loss” line item of the Condensed Consolidated Statements of Operations reported for both periods.

The information in this Current Report on Form 8-K/A, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.
(d) Exhibits .
 
Exhibit
 
 
No.
  
Description
 
 
99.1
  




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
                                

 
 
MODERNA, INC.
 
 
 
Date: May 9, 2019
By:
/s/ Lorence Kim, M.D.
 
 
 
 
 
Lorence Kim, M.D.
 
 
Chief Financial Officer
 
 
 



Moderna (MM) (NASDAQ:MRNA)
Historical Stock Chart

1 Year : From Jul 2018 to Jul 2019

Click Here for more Moderna (MM) Charts.

Moderna (MM) (NASDAQ:MRNA)
Intraday Stock Chart

Today : Tuesday 23 July 2019

Click Here for more Moderna (MM) Charts.

Latest MRNA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.